Daniela is a Managing Director at EQT Life Sciences and she has been part of the team since 2023. While at EQT, she has invested in SpliceBio and Mosanna Therapeutics, while supporting other portfolio companies, such as Varmx. Prior to EQT, Daniela was a Principal at Inkef in Amsterdam, where she worked on several biotech investments, including Cardior (sold to Novo Nordisk for up to $1.1Bn). Before joining Inkef, she was an Analyst at M Ventures.

Daniela holds a PhD in molecular biology from Heidelberg University, obtained as an early Stage Researcher with Marie Skłodowska-Curie Actions, and MSc and BSc in Biotechnology from University of Padova.